{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:40:36Z","timestamp":1791639636808,"version":"4.3.4"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.yrtph.2022.105166","type":"journal-article","created":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T22:03:09Z","timestamp":1649455389000},"page":"105166","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Preclinical safety assessment of toxicity and biodistribution of oncolytic virus HSV-1 expressing human PD-1 antibody in mice"],"prefix":"10.1016","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6644-856X","authenticated-orcid":false,"given":"Xin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufa","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaopeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingchao","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.yrtph.2022.105166_bib1","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1517\/14740338.2013.795944","article-title":"Cancer immunotherapies, their safety and toxicity","volume":"12","author":"Alatrash","year":"2013","journal-title":"Expet Opin. Drug Saf."},{"issue":"1","key":"10.1016\/j.yrtph.2022.105166_bib2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.trecan.2016.11.009","article-title":"Targeted therapy and immunosuppression in the tumor microenvironment","volume":"3","author":"Allegrezza","year":"2017","journal-title":"Trends Cancer"},{"key":"10.1016\/j.yrtph.2022.105166_bib3","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ebiom.2019.07.066","article-title":"Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma","volume":"47","author":"Andtbacka","year":"2019","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.yrtph.2022.105166_bib4","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1128\/jvi.68.1.48-55.1994","article-title":"ICP34.5 mutants of herpes simplex virus type 1 strain 17syn+ are attenuated for neurovirulence in mice and for replication in confluent primary mouse embryo cell cultures","volume":"68","author":"Bolovan","year":"1994","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.yrtph.2022.105166_bib5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/gb-2005-6-6-223","article-title":"The B7 family of immune-regulatory ligands","volume":"6","author":"Collins","year":"2005","journal-title":"Genome Biol."},{"key":"10.1016\/j.yrtph.2022.105166_bib6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.pharmthera.2017.07.005","article-title":"Toxicity profile of immunotherapy","volume":"181","author":"Cousin","year":"2017","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.yrtph.2022.105166_bib7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/jat.727","article-title":"A good practice guide to the administration of substances and removal of blood, including routes and volumes","volume":"21","author":"Diehl","year":"2001","journal-title":"J. Appl. Toxicol."},{"issue":"11","key":"10.1016\/j.yrtph.2022.105166_bib8","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1038\/mt.2014.160","article-title":"CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy","volume":"22","author":"Engeland","year":"2014","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.yrtph.2022.105166_bib9","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nri.2016.134","article-title":"Mechanisms of immunomodulation by mammalian and viral decoy receptors: insights from structures","volume":"17","author":"Felix","year":"2017","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.yrtph.2022.105166_bib10","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s40259-016-0189-y","article-title":"Talimogene laherparepvec: a review in unresectable metastatic melanoma","volume":"30","author":"Garnock-Jones","year":"2016","journal-title":"BioDrugs"},{"issue":"10","key":"10.1016\/j.yrtph.2022.105166_bib11","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1220467","article-title":"Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition","volume":"5","author":"Kleinpeter","year":"2016","journal-title":"OncoImmunology"},{"issue":"9","key":"10.1016\/j.yrtph.2022.105166_bib12","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2174\/1389201016666150619114554","article-title":"Immunotherapy approaches in cancer treatment","volume":"16","author":"Klener","year":"2015","journal-title":"Curr. Pharmaceut. Biotechnol."},{"issue":"2","key":"10.1016\/j.yrtph.2022.105166_bib13","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1089\/hum.2017.238","article-title":"Application of virus vector-mediated gene therapy in China","volume":"29","author":"Lin","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.yrtph.2022.105166_bib14","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/bs.acr.2019.03.002","article-title":"From immune checkpoints to vaccines: the past, present and future of cancer immunotherapy","volume":"143","author":"Osipov","year":"2019","journal-title":"Adv. Cancer Res."},{"issue":"6","key":"10.1016\/j.yrtph.2022.105166_bib15","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.yrtph.2022.105166_bib16","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ymthe.2018.01.019","article-title":"Pre-existing immunity to oncolytic virus potentiates its immunotherapeutic efficacy","volume":"26","author":"Ricca","year":"2018","journal-title":"Mol. Ther."},{"issue":"7","key":"10.1016\/j.yrtph.2022.105166_bib17","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russell","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.yrtph.2022.105166_bib18","first-page":"183","article-title":"Toxicology and biodistribution: the clinical value of animal biodistribution studies","volume":"8","author":"Silva Lima","year":"2018","journal-title":"Mol. Ther. Methods"},{"issue":"5","key":"10.1016\/j.yrtph.2022.105166_bib19","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nrg1066","article-title":"Progress and problems with the use of viral vectors for gene therapy","volume":"4","author":"Thomas","year":"2003","journal-title":"Nat. Rev. Genet."},{"issue":"518","key":"10.1016\/j.yrtph.2022.105166_bib20","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.canlet.2021.06.005","article-title":"Enhanced anti-tumor response elicited by a novel oncolytic HSV-1 engineered with an anti-PD-1 antibody","volume":"1010","author":"Tian","year":"2021","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.yrtph.2022.105166_bib21","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1089\/10430349950018832","article-title":"Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity","volume":"10","author":"Toda","year":"1999","journal-title":"Hum. Gene Ther."},{"issue":"11","key":"10.1016\/j.yrtph.2022.105166_bib22","first-page":"6396","article-title":"Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing","volume":"98","author":"Todo","year":"2001","journal-title":"PANS (Pest. Artic. News Summ.)"},{"issue":"7","key":"10.1016\/j.yrtph.2022.105166_bib23","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s41568-018-0009-4","article-title":"Oncolytic viruses as engineering platforms for combination immunotherapy","volume":"18","author":"Twumasi-Boateng","year":"2018","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"10.1016\/j.yrtph.2022.105166_bib24","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1089\/104303401750195944","article-title":"Preclinical safety evaluation of G207, a replication- competent herpes simplex virus type 1, inoculated intraprostatically in mice and nonhuman primates","volume":"12","author":"Varghese","year":"2001","journal-title":"Hum. Gene Ther."}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230022000538?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230022000538?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T12:33:15Z","timestamp":1759494795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0273230022000538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":24,"alternative-id":["S0273230022000538"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2022.105166","relation":{},"ISSN":["0273-2300"],"issn-type":[{"value":"0273-2300","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical safety assessment of toxicity and biodistribution of oncolytic virus HSV-1 expressing human PD-1 antibody in mice","name":"articletitle","label":"Article Title"},{"value":"Regulatory Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yrtph.2022.105166","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"105166"}}